Changes in emergency department blood product use for major paediatric trauma following the implementation of a major haemorrhage protocol

2021 ◽  
Author(s):  
Elliot Long ◽  
Amanda Williams ◽  
Franz E Babl ◽  
Anne Kinmonth ◽  
Wai Chung Tse ◽  
...  
Keyword(s):  
Emergency Department ◽  
Blood Product ◽  
Major Haemorrhage ◽  
Product Use ◽  
Paediatric Trauma

Improving emergency department blood product use through nursing education

Transfusion ◽  
2020 ◽  
Vol 60 (6) ◽  
pp. 1227-1230
Author(s):  
Melora C. Riveira ◽  
Tim A. Fredrickson ◽  
Bryant R. Iha ◽  
Steven H. Mitchell ◽  
Nathan J. White ◽  
...  
Keyword(s):  
Emergency Department ◽  
Nursing Education ◽  
Blood Product ◽  
Product Use

Massive transfusion in paediatric trauma: a single centre experience

2010 ◽  
Vol 27 (Suppl 1) ◽  
pp. A10.3-A11
Author(s):  
Robert Hearn
Keyword(s):  
Emergency Department ◽  
Major Trauma ◽  
Massive Transfusion ◽  
Damage Control ◽  
Penetrating Trauma ◽  
Damage Control Surgery ◽  
Blood Parameters ◽  
Major Haemorrhage ◽  
Blood Products ◽  
Paediatric Trauma

AimsTo report the occurrence of major haemorrhage in children following major trauma, the practice of blood products transfusion including monitoring of laboratory parameters in such patients and the outcomes.MethodsWe retrospectively analysed the local paediatric trauma database of all children following trauma call activation on arrival to the Emergency Department in a major urban trauma centre in London. We studies over a period of 15 months, May 2008–August 2009. We defined massive transfusion as packed red cells >40 ml/kg in the first 4 h or >80 ml/kg in the first 24 h.Results227 children presented to the accidents and emergency during this period following major trauma call activation. The median age at presentation was 10.2 years. 13 (5.7%) children had major haemorrhage. The median ISS WAS 35 (IQR 10–60). All but one were males. Three had penetrating trauma, one of whom made it to theatre but all died. Four had emergency damage control surgery. Abnormal results were seen in three patients, each having one abnormal result (INR=1.9 and APTT=86, low Hb=7.6, thrombocytopaenia =63). 8/13 patients received additional blood products such as Fresh Frozen Plasma (FFP), platelets and Cryoprecipitate. However, no patient received the ration of blood products RBC:FFP of 1:1 as practised in adult trauma. Two patients had no admission bloods done. Worsening coagulation parameters were seen in two patients when measure post-transfusion and the remaining 11 patients did not have routine monitoring of blood parameters post-transfusion. 8 (62%) patients died of which 7 died in the Emergency Department.ConclusionsMajor haemorrhage is associated with a very high mortality in severely injured children. There is a need for instituting a major haemorrhage policy in paediatric trauma and consideration of point-of-care testing of blood parameters.

Predictive Factors for High Blood Product Use in Patients with Acute Stanford Type A Dissection

2020 ◽  
Author(s):  
M. J. Schafigh ◽  
M. Hamiko ◽  
W. Schiller ◽  
H. Treede ◽  
C. Probst
Keyword(s):  
Predictive Factors ◽  
Blood Product ◽  
Type A ◽  
Product Use ◽  
Type A Dissection

scholarly journals Abnormal Calcium Levels During Trauma Resuscitation Are Associated With Increased Mortality, Increased Blood Product Use, and Greater Hospital Resource Consumption

2017 ◽  
Vol 125 (3) ◽  
pp. 895-901 ◽  
Author(s):  
Emily J. MacKay ◽  
Michael D. Stubna ◽  
Daniel N. Holena ◽  
Patrick M. Reilly ◽  
Mark J. Seamon ◽  
...  
Keyword(s):  
Blood Product ◽  
Resource Consumption ◽  
Hospital Resource ◽  
Trauma Resuscitation ◽  
Product Use

scholarly journals The Impact of Perioperative Viscoelastic Test Application on Blood Product Usage and Outcome in Cardiac Surgery; Regional Cardiac Surgery Center Experience

2021 ◽  
Author(s):  
Murat Aksun ◽  
Saliha Aksun ◽  
Mehmet Ali Çoşar ◽  
Elif Neziroğlu ◽  
Senem Girgin ◽  
...  
Keyword(s):  
Cardiac Surgery ◽  
Clinical Experience ◽  
Heart Surgery ◽  
Blood Product ◽  
Open Heart Surgery ◽  
Control Group ◽  
Open Heart ◽  
Blood Products ◽  
Product Use ◽  
The Impact

Objective: Thromboelastography (TEG) is a diagnostic modality that gives information about coagulation. Despite all blood-preserving precautions in open heart surgery there are blood losses and the use of blood and blood products becomes inevitable. TEG is mostly not available in every center and habits, trends and clinical experience in blood use create the possibility of causing unnecessary use of blood and blood products. In this study, it was aimed to determine the effect of the use of thromboelastography on the use of blood and blood products in cardiac surgery. Methods: Two hundred patients between 18-70 years old who underwent open heart surgery were included in the study. After the cardiopulmonary bypass (CPB), the cases were confirmed to have an Activated Clotting Time (ACT) value in the range of 120-150 sec after protamine administration. In 100 patients in the TEG group, the coagulation status was evaluated with TEG and it was decided how to apply blood and blood product use. Blood and blood product use was applied to 100 patients in the control group based on clinical experience and foresight. The total amount of blood and blood product used, fluid balance, need for inotropics, mechanical ventilator time, complications, duration of intensive care and discharge times were recorded. Results: Use of Fresh Frozen Plasma (FFP) at the after CPB in the TEG group was statistically significantly lower than that of the control group FFP (p<0.05). Postoperative FFP and postoperative platelet use in the study group were statistically significantly lower than in the postoperative FFP and postoperative platelet values of the control group (p <0.05). Conclusion: The use of thromboelastography is a very useful monitoring in terms of reducing FFP use after CPB and reducing FFP and platelet usage in the postoperative period. In this way, the unnecessary use of blood and blood products can be prevented.

Comparison of blood product use and costs with use of 3-factor versus 4-factor prothrombin complex concentrate for off-label indications

2018 ◽  
Vol 75 (15) ◽  
pp. 1103-1109 ◽  
Author(s):  
Jessica DeAngelo ◽  
Daniel H. Jarrell ◽  
Richard Cosgrove ◽  
James Camamo ◽  
Christopher J. Edwards ◽  
...  
Keyword(s):  
Prothrombin Complex Concentrate ◽  
Blood Product ◽  
Factor Versus ◽  
Off Label ◽  
Product Use

Blood product support

2007 ◽  
pp. 501-510
Keyword(s):  
Blood Product ◽  
Intensive Chemotherapy ◽  
Blood Products ◽  
Product Use ◽  
Remission Rates ◽  
Nurses Role ◽  
British Committee

Blood products 502 The nurses' role in blood product transfusions 508 The introduction of safe, reliable blood products has enabled the development of intensive chemotherapy programmes for a variety of malignancies. This has led to significantly improved remission rates. It must be remembered however that blood product use is not without risks, and that these are a very expensive resource. The pool of acceptable donors is also diminishing because of more stringent screening. Blood products should only be used in appropriate situations in consultation with national and local guidelines. (See British Committee for Standards in Haematology, BCSH...

Sign in / Sign up

Export Citation Format

Share Document